Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Ambio Pharmaceuticals / Equity Capital Markets

AmbioPharm, a leading global peptide CDMO player, plans to raise up to USD 300m via a Hong Kong listing.The company ranked number four globally for the peptide CDMO which is a specialized segment in the landscape of the overall CDMO market. We like the company's market leadership and its growth. The company is monetizing its expertise by collaborating with biotech and pharmaceutical companies to develop peptide biosimilars benchmarking to block buster diabetes peptide drugs. With quality pre-IPO investors, experienced management team and interesting business model, we think investors should follow the IPO.

AmbioPharm, a leading global peptide CDMO player, plans to raise up to USD 300m via a Hong Kong listing.The company ranked number four globally for the peptide CDMO which is a specialized segment in the landscape of the overall CDMO market. We like the company's market leadership and its growth. The company is monetizing its expertise by collaborating with biotech and pharmaceutical companies to develop peptide biosimilars benchmarking to block buster diabetes peptide drugs. With quality pre-IPO investors, experienced management team and interesting business model, we think investors should follow the IPO.

AmbioPharm (昂博制药) Pre-IPO: Peptide CDMO Leader Turning Licensor

Quantitative Analysis

In our weekly HK Connect Flow series, we aim to highlight key stocks and sectors which the mainland investors traded via the southbound Hong Kong Connect, as analyzed by our proprietary data engine. Since the opening of Hong Kong Connect scheme in 2014, southbound Chinese money started to play an increasingly important role in the Hong Kong stock market. In a Hong Kong exchange report released in July 2019, the exchange highlighted that flows from mainland China accounted for 12% of the total trading volume in the market and is ahead of the US investors' 10% and UK investors' 7% share respectively.  We split the stocks eligible for the Hong Kong Connect trade into three groups: HSCEI component stocks, stocks with a market capitalization between USD 1 billion and USD 5 billion, and stocks with a market capitalization between USD 500 million and USD 1 billion. In this insight, we will highlight inflows into China Mobile Limited (941 HK), and Geely Automobile Holdings Limited (175 HK), as well as outflows from Wuxi Biologics (Cayman) Inc. (2269 HK), Tencent Holdings Limited (700 HK), and Xiaomi Corporation (1810 HK).

In our weekly HK Connect Flow series, we aim to highlight key stocks and sectors which the mainland investors traded via the southbound Hong Kong Connect, as analyzed by our proprietary data engine.  Since the opening of Hong Kong Connect scheme in 2014, southbound Chinese money started to play an increasingly important role in the Hong Kong stock market. In a Hong Kong exchange report released in July 2019, the exchange highlighted that flows from mainland China accounted for 12% of the total trading volume in the market and is ahead of the US investors' 10% and UK investors' 7% share respectively.   We split the stocks eligible for the Hong Kong Connect trade into three groups: HSCEI component stocks, stocks with a market capitalization between USD 1 billion and USD 5 billion, and stocks with a market capitalization between USD 500 million and USD 1 billion.  In this insight, we will highlight inflows into China Mobile Limited (941 HK), and Geely Automobile Holdings Limited (175 HK), as well as outflows from Wuxi Biologics (Cayman) Inc. (2269 HK), Tencent Holdings Limited (700 HK), and Xiaomi Corporation (1810 HK).

Hong Kong Connect Flows: Wuxi Biologics, Tencent, Xiaomi Led Outflows

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Asymchem Laboratories Tianjin / Equity Bottom-Up

On August 15, 2021, <a href="https://www.smartkarma.com/entities/asymchem-laboratories-tianjin-co-ltd" target="_blank" data-smartkarma-citation="entities:28265:1" rel="noopener">Asymchem Laboratories (002821 CH)</a> released its 2021/1H financial results. In the first half of 2021, the revenue of Asymchem was RMB1.76 billion, up 39.04% YoY. Net profit attributed to shareholders was RMB429 million, up 36.03% YoY. Net profit after deducting non-recurring gains and losses was RMB353 million, up 27.29% YoY. Obviously, the market is not satisfied with the performance. On August 16, Asymchem share price decreased by 10%. Meanwhile, the star institution Hillhouse Capital significantly reduced its holdings of about 2.2 million shares, which could lead to more concerns from the investors. This article mainly analyzed the performance of Asymchem in 2021/1H, the concerns and the outlook of the Company.

On August 15, 2021, Asymchem Laboratories (002821 CH) released its 2021/1H financial results. In the first half of 2021, the revenue of Asymchem was RMB1.76 billion, up 39.04% YoY. Net profit attributed to shareholders was RMB429 million, up 36.03% YoY. Net profit after deducting non-recurring gains and losses was RMB353 million, up 27.29% YoY. Obviously, the market is not satisfied with the performance. On August 16, Asymchem share price decreased by 10%. Meanwhile, the star institution Hillhouse Capital significantly reduced its holdings of about 2.2 million shares, which could lead to more concerns from the investors. This article mainly analyzed the performance of Asymchem in 2021/1H, the concerns and the outlook of the Company. 

Asymchem Laboratories (002821.CH) 2021H1 Results - Not Good Enough

Asymchem Laboratories Tianjin / Equity Capital Markets

On June 28, 2021, <a href="https://www.smartkarma.com/entities/asymchem-laboratories-tianjin-co-ltd" target="_blank" data-smartkarma-citation="entities:28265:1" rel="noopener">Asymchem Laboratories (002821 CH)</a>, the fifth largest drug substance CDMO globally and the largest China-based commercial stage chemical drug CDMO, submitted its listing application to the HKEX, which means that, after <a href="https://www.smartkarma.com/entities/wuxi-apptec-co-ltd-bf4a1265-beef-48b6-b82d-29308426030f" target="_blank" data-smartkarma-citation="entities:27795:1" rel="noopener">WuXi AppTec Co. Ltd. (2359 HK)</a>, <a href="https://www.smartkarma.com/entities/hangzhou-tigermed-consulting-co-ltd-1008d609-73bd-4d76-8315-b29502a448ff" target="_blank" data-smartkarma-citation="entities:29212:1" rel="noopener">Hangzhou Tigermed Consulting (H) (3347 HK) </a>and <a href="https://www.smartkarma.com/entities/pharmaron-beijing-co-ltd" target="_blank" data-smartkarma-citation="entities:28428:1" rel="noopener">Pharmaron Beijing Co Ltd-H (3759 HK)</a>, there would be another A+H listed CXO company in China. This insight mainly analyzed the industry characteristics, the strength and the concerns of Asymchem.

On June 28, 2021, Asymchem Laboratories (002821 CH), the fifth largest drug substance CDMO globally and the largest China-based commercial stage chemical drug CDMO, submitted its listing application to the HKEX, which means that, after WuXi AppTec Co. Ltd. (2359 HK), Hangzhou Tigermed Consulting (H) (3347 HK) and Pharmaron Beijing Co Ltd-H (3759 HK), there would be another A+H listed CXO company in China. This insight mainly analyzed the industry characteristics, the strength and the concerns of Asymchem.

Pre-IPO Asymchem Laboratories - The Strength and the Concerns

In our weekly HK Connect Flow series, we aim to highlight key stocks and sectors which the mainland investors traded via the southbound Hong Kong Connect, as analyzed by our proprietary data engine.Since the opening of Hong Kong Connect scheme in 2014, southbound Chinese money started to play an increasingly important role in the Hong Kong stock market. In a Hong Kong exchange report released in July 2019, the exchange highlighted that flows from mainland China accounted for 12% of the total trading volume in the market and is ahead of the US investors' 10% and UK investors' 7% share respectively. We split the stocks eligible for the Hong Kong Connect trade into three groups: HSCEI component stocks, stocks with a market capitalization between USD 1 billion and USD 5 billion, and stocks with a market capitalization between USD 500 million and USD 1 billion.In this insight, we will highlight inflows into Semiconductor Manufacturing International Corporation (981 HK), Cosco Shipping Holdings Co., Ltd. (1919 HK), Wuxi Biologics (Cayman) Inc. (2269 HK), Geely Automobile Holdings Limited (175 HK), as well as outflows from Tencent Holdings Limited (700 HK), and Meituan (3690 HK).

In our weekly HK Connect Flow series, we aim to highlight key stocks and sectors which the mainland investors traded via the southbound Hong Kong Connect, as analyzed by our proprietary data engine.Since the opening of Hong Kong Connect scheme in 2014, southbound Chinese money started to play an increasingly important role in the Hong Kong stock market. In a Hong Kong exchange report released in July 2019, the exchange highlighted that flows from mainland China accounted for 12% of the total trading volume in the market and is ahead of the US investors' 10% and UK investors' 7% share respectively. We split the stocks eligible for the Hong Kong Connect trade into three groups: HSCEI component stocks, stocks with a market capitalization between USD 1 billion and USD 5 billion, and stocks with a market capitalization between USD 500 million and USD 1 billion.In this insight, we will highlight inflows into Semiconductor Manufacturing International Corporation (981 HK), Cosco Shipping Holdings Co., Ltd. (1919 HK), Wuxi Biologics (Cayman) Inc. (2269 HK), Geely Automobile Holdings Limited (175 HK), as well as outflows from Tencent Holdings Limited (700 HK), and Meituan (3690 HK).

Hong Kong Connect Flows: Inflows into SMIC & Autos

China

WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland.  We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions. 

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Wuxi Biologics (2269 HK)

AmbioPharm (昂博制药) Pre-IPO: Peptide CDMO Leader Turning Licensor

AmbioPharm is a global leader in the peptide CDMO business and will further monetizing its expertise by collaborating with partners to develop...

Ke Yan, CFA, FRM

Hong Kong Connect Flows: Wuxi Biologics, Tencent, Xiaomi Led Outflows

We highlight top three stocks that led the outflows last week were Wuxi Biologics (2269 HK), Tencent (700 HK), and Xiaomi (1810 HK).

Ke Yan, CFA, FRM

Asymchem Laboratories (002821.CH) 2021H1 Results - Not Good Enough

This article analyzed Asymchem in terms of its 2021/1H financial results, the comparison with peers, the concerns on growth, the valuation and the...

Xinyao (Criss) Wang

Pre-IPO Asymchem Laboratories - The Strength and the Concerns

The article mainly analyzed Asymchem Laboratories in terms of the industry characteristics, the strength of its business, the comparison with...

Xinyao (Criss) Wang

Hong Kong Connect Flows: Inflows into SMIC & Autos

We will highlight weekly top inflows into SMIC (981 HK), Cosco Shipping (1919 HK), Wuxi Biologics (2269 HK), Geely Automobile Holdings Limited (175...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)